登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 35 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 35
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
- 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
- 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
- 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
- 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心河南医药大学第一附属医院First Affiliated Hospital of Xinxiang Medical University新乡医院页面
- 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
- 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
- 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心宁夏医科大学总医院General Hospital of Ningxia Medical University银川医院页面
- 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江门市中心医院Jiangmen Central Hospital江门医院页面
- 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
- 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
- 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
- 研究中心临沂市人民医院Linyi People's Hospital临沂医院页面
- 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心哈尔滨医科大学附属第二医院Second Affiliated Hospital of Harbin Medical University哈尔滨医院页面
- 研究中心遵义医科大学第二附属医院Second Affiliated Hospital of Zunyi Medical University遵义医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心山东省立医院Shandong Provincial Hospital济南医院页面
- 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
- 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
- 研究中心空军军医大学唐都医院Tangdu Hospital西安医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07010263,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed small cell lung cancer.
入选标准第 5 条
Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage.
入选标准第 6 条
Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.
入选标准第 9 条
Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
排除标准第 2 条
Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
排除标准第 6 条
Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
排除标准第 11 条
Subjects requiring systemic treatment with corticosteroids (>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
排除标准第 14 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 3 条
Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
排除标准第 1 条
History of active malignant tumors within the previous 5 years.
排除标准第 5 条
Pregnant or lactating women.
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07010263,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The subjects voluntarily participated in the study with full informed consent and signed written informed consent form. Aged ≥18 years on day fo signing the informed consent. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy ≥ 3 months Histologically or cytologically confirmed small cell lung cancer. Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage. Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy. Adequate organ function. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.排除标准:Exclusion Criteria:
Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components. Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia. Symptoms or signs of primary disease deterioration that the investigator judges clinically unacceptable, such as cachexia. Presence of pleural effusion, pericardial effusion, or ascites, which was clinically symptomatic or requiring frequent drainage. History of active malignant tumors within the previous 5 years. Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug. Uncontrolled comorbidities, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, and other related diseases.. Have serious neurological or mental illnesses, including dementia and epileptic seizures. Pregnant or lactating women. Have cardiovascular or cerebrovascular diseases or risk factors. Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs. Prior treatments targeting immune mechanisms, including, but not limited to, immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy. Prior treatments with anti-angiogenic therapy. Subjects requiring systemic treatment with corticosteroids (>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug. Known history of severe hypersensitivity reactions to other monoclonal antibodies or with a known history of allergy or hypersensitivity reactions to any of study drugs or their components. Active autoimmune diseases that require systemic treatment within 2 years prior to the study, or autoimmune diseases that the investigator judges to be potentially recurrent or require planned treatment. Known interstitial lung disease or non infectious pneumonia, which currently has symptoms or requires systemic corticosteroid treatment in the past,or investigator juges may affect the toxicity assessment or management related to the study treatment. Known severe infection within 4 weeks prior to the first dose of study drug. Known active tuberculosis. Known active syphilis infection. Known history of immunodeficiency or positive HIV test results. .Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. Active hepatitis B or active hepatitis C. Received a live vaccine within 30 days prior to the first dose of study drug, or planning to receive a live vaccine during the study period.
引自 ClinicalTrials.gov, NCT07010263, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07010263,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。